VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors

Jun Wang, Feng Luo, Jean J. Lu, Peter K. Chen, Paul Liu, Wenxin Zheng

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) is a heparinbinding, dimeric polypeptide with potent mitogenic effects on endothelial cells. VEGF expression has also been reported in ovarian epithelial tumors (OETs), which may be associated with gonadotropin stimulatioin. We recently reported that most OETs, including OET cell lines, express gonadotropin receptors. Here we studied VEGF mRNA expression in 141 OET and 35 benign ovarian samples using reverse transcriptase polymerase chain reaction and in situ hybridization (ISH). We also studied VEGF production by OET cell lines under stimulation of gonadotropins. AO (serous carcinoma), low malignant potential (LMP; SV40-transformed borderline tumor) and ML-5 (SV40-transformed cystadenoma) cells were examined for VEGF protein production under the regulation of gonadotropins in vitro. The biologic function of VEGF was confirmed by using bovine endothelial growth assay. Whereas VEGF was not detected in benign ovarian surface epithelium or in ovarian epithelial inclusions, it was detected in both epithelial and stromal compartments of OETs. For VEGF epithelial expression, only 5% of ovarian cystadenomas and 30% of borderline tumors were positive for VEGF detection by ISH, whereas VEGF mRNA signal was detected in 80% of ovarian carcinoma cases. This increment of VEGF expression in ovarian carcinomas was statistically significant compared with benign and borderline tumors. Within ovarian carcinomas, the percentage of VEGF-positive cells was significantly associated with the grade of cancer but not with cancer cell types or cancer stages. Both folliclestimulating hormone (FSH) and luteinizing hormone (LH) stimulated the expression of VEFG165 in AO cells in a dosedependent manner. Maximal induction was obtained for FSH at dose of 40 mlU/ml and for LH at 50 mlU/ml after 48 hr of culture. Compared with the nonstimulated cells, VEGF level was significantly elevated in both LMP and AO cells after stimulation of gonadotropins. Furthermore, the induction of VEGF expression was significantly stronger in carcinoma cells than in borderline OET cells. These observations suggest that VEGF may play a role in the development of ovarian cancer and that the elevated gonadotropins, as found in menopause and in most ovarian cancer patients after surgery, could accelerate tumor growth and tumor recurrence by inducing VEGF expression in OETs.

Original languageEnglish (US)
Pages (from-to)163-167
Number of pages5
JournalInternational Journal of Cancer
Volume97
Issue number2
DOIs
StatePublished - Jan 10 2002

Fingerprint

Gonadotropins
Vascular Endothelial Growth Factor A
Neoplasms
Carcinoma
Cystadenoma
Epithelial Cells
Luteinizing Hormone
Tumor Cell Line
Ovarian Neoplasms
In Situ Hybridization
Gonadotropin Receptors
Hormones
Messenger RNA
Growth
Menopause
Reverse Transcriptase Polymerase Chain Reaction

Keywords

  • Gonadotropins
  • Ovarian epithelial cancer
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. / Wang, Jun; Luo, Feng; Lu, Jean J.; Chen, Peter K.; Liu, Paul; Zheng, Wenxin.

In: International Journal of Cancer, Vol. 97, No. 2, 10.01.2002, p. 163-167.

Research output: Contribution to journalArticle

Wang, Jun ; Luo, Feng ; Lu, Jean J. ; Chen, Peter K. ; Liu, Paul ; Zheng, Wenxin. / VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. In: International Journal of Cancer. 2002 ; Vol. 97, No. 2. pp. 163-167.
@article{68c0326794754377aae483eafb55e4f2,
title = "VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors",
abstract = "Vascular endothelial growth factor (VEGF) is a heparinbinding, dimeric polypeptide with potent mitogenic effects on endothelial cells. VEGF expression has also been reported in ovarian epithelial tumors (OETs), which may be associated with gonadotropin stimulatioin. We recently reported that most OETs, including OET cell lines, express gonadotropin receptors. Here we studied VEGF mRNA expression in 141 OET and 35 benign ovarian samples using reverse transcriptase polymerase chain reaction and in situ hybridization (ISH). We also studied VEGF production by OET cell lines under stimulation of gonadotropins. AO (serous carcinoma), low malignant potential (LMP; SV40-transformed borderline tumor) and ML-5 (SV40-transformed cystadenoma) cells were examined for VEGF protein production under the regulation of gonadotropins in vitro. The biologic function of VEGF was confirmed by using bovine endothelial growth assay. Whereas VEGF was not detected in benign ovarian surface epithelium or in ovarian epithelial inclusions, it was detected in both epithelial and stromal compartments of OETs. For VEGF epithelial expression, only 5{\%} of ovarian cystadenomas and 30{\%} of borderline tumors were positive for VEGF detection by ISH, whereas VEGF mRNA signal was detected in 80{\%} of ovarian carcinoma cases. This increment of VEGF expression in ovarian carcinomas was statistically significant compared with benign and borderline tumors. Within ovarian carcinomas, the percentage of VEGF-positive cells was significantly associated with the grade of cancer but not with cancer cell types or cancer stages. Both folliclestimulating hormone (FSH) and luteinizing hormone (LH) stimulated the expression of VEFG165 in AO cells in a dosedependent manner. Maximal induction was obtained for FSH at dose of 40 mlU/ml and for LH at 50 mlU/ml after 48 hr of culture. Compared with the nonstimulated cells, VEGF level was significantly elevated in both LMP and AO cells after stimulation of gonadotropins. Furthermore, the induction of VEGF expression was significantly stronger in carcinoma cells than in borderline OET cells. These observations suggest that VEGF may play a role in the development of ovarian cancer and that the elevated gonadotropins, as found in menopause and in most ovarian cancer patients after surgery, could accelerate tumor growth and tumor recurrence by inducing VEGF expression in OETs.",
keywords = "Gonadotropins, Ovarian epithelial cancer, VEGF",
author = "Jun Wang and Feng Luo and Lu, {Jean J.} and Chen, {Peter K.} and Paul Liu and Wenxin Zheng",
year = "2002",
month = "1",
day = "10",
doi = "10.1002/ijc.1593",
language = "English (US)",
volume = "97",
pages = "163--167",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors

AU - Wang, Jun

AU - Luo, Feng

AU - Lu, Jean J.

AU - Chen, Peter K.

AU - Liu, Paul

AU - Zheng, Wenxin

PY - 2002/1/10

Y1 - 2002/1/10

N2 - Vascular endothelial growth factor (VEGF) is a heparinbinding, dimeric polypeptide with potent mitogenic effects on endothelial cells. VEGF expression has also been reported in ovarian epithelial tumors (OETs), which may be associated with gonadotropin stimulatioin. We recently reported that most OETs, including OET cell lines, express gonadotropin receptors. Here we studied VEGF mRNA expression in 141 OET and 35 benign ovarian samples using reverse transcriptase polymerase chain reaction and in situ hybridization (ISH). We also studied VEGF production by OET cell lines under stimulation of gonadotropins. AO (serous carcinoma), low malignant potential (LMP; SV40-transformed borderline tumor) and ML-5 (SV40-transformed cystadenoma) cells were examined for VEGF protein production under the regulation of gonadotropins in vitro. The biologic function of VEGF was confirmed by using bovine endothelial growth assay. Whereas VEGF was not detected in benign ovarian surface epithelium or in ovarian epithelial inclusions, it was detected in both epithelial and stromal compartments of OETs. For VEGF epithelial expression, only 5% of ovarian cystadenomas and 30% of borderline tumors were positive for VEGF detection by ISH, whereas VEGF mRNA signal was detected in 80% of ovarian carcinoma cases. This increment of VEGF expression in ovarian carcinomas was statistically significant compared with benign and borderline tumors. Within ovarian carcinomas, the percentage of VEGF-positive cells was significantly associated with the grade of cancer but not with cancer cell types or cancer stages. Both folliclestimulating hormone (FSH) and luteinizing hormone (LH) stimulated the expression of VEFG165 in AO cells in a dosedependent manner. Maximal induction was obtained for FSH at dose of 40 mlU/ml and for LH at 50 mlU/ml after 48 hr of culture. Compared with the nonstimulated cells, VEGF level was significantly elevated in both LMP and AO cells after stimulation of gonadotropins. Furthermore, the induction of VEGF expression was significantly stronger in carcinoma cells than in borderline OET cells. These observations suggest that VEGF may play a role in the development of ovarian cancer and that the elevated gonadotropins, as found in menopause and in most ovarian cancer patients after surgery, could accelerate tumor growth and tumor recurrence by inducing VEGF expression in OETs.

AB - Vascular endothelial growth factor (VEGF) is a heparinbinding, dimeric polypeptide with potent mitogenic effects on endothelial cells. VEGF expression has also been reported in ovarian epithelial tumors (OETs), which may be associated with gonadotropin stimulatioin. We recently reported that most OETs, including OET cell lines, express gonadotropin receptors. Here we studied VEGF mRNA expression in 141 OET and 35 benign ovarian samples using reverse transcriptase polymerase chain reaction and in situ hybridization (ISH). We also studied VEGF production by OET cell lines under stimulation of gonadotropins. AO (serous carcinoma), low malignant potential (LMP; SV40-transformed borderline tumor) and ML-5 (SV40-transformed cystadenoma) cells were examined for VEGF protein production under the regulation of gonadotropins in vitro. The biologic function of VEGF was confirmed by using bovine endothelial growth assay. Whereas VEGF was not detected in benign ovarian surface epithelium or in ovarian epithelial inclusions, it was detected in both epithelial and stromal compartments of OETs. For VEGF epithelial expression, only 5% of ovarian cystadenomas and 30% of borderline tumors were positive for VEGF detection by ISH, whereas VEGF mRNA signal was detected in 80% of ovarian carcinoma cases. This increment of VEGF expression in ovarian carcinomas was statistically significant compared with benign and borderline tumors. Within ovarian carcinomas, the percentage of VEGF-positive cells was significantly associated with the grade of cancer but not with cancer cell types or cancer stages. Both folliclestimulating hormone (FSH) and luteinizing hormone (LH) stimulated the expression of VEFG165 in AO cells in a dosedependent manner. Maximal induction was obtained for FSH at dose of 40 mlU/ml and for LH at 50 mlU/ml after 48 hr of culture. Compared with the nonstimulated cells, VEGF level was significantly elevated in both LMP and AO cells after stimulation of gonadotropins. Furthermore, the induction of VEGF expression was significantly stronger in carcinoma cells than in borderline OET cells. These observations suggest that VEGF may play a role in the development of ovarian cancer and that the elevated gonadotropins, as found in menopause and in most ovarian cancer patients after surgery, could accelerate tumor growth and tumor recurrence by inducing VEGF expression in OETs.

KW - Gonadotropins

KW - Ovarian epithelial cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0037050012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037050012&partnerID=8YFLogxK

U2 - 10.1002/ijc.1593

DO - 10.1002/ijc.1593

M3 - Article

C2 - 11774259

AN - SCOPUS:0037050012

VL - 97

SP - 163

EP - 167

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -